Compare BNR & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNR | TLSI |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | China | United States |
| Employees | N/A | 110 |
| Industry | Medical Specialities | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.7M | 267.1M |
| IPO Year | 2019 | N/A |
| Metric | BNR | TLSI |
|---|---|---|
| Price | $16.20 | $4.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 31.2K | ★ 190.8K |
| Earning Date | 03-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $111.65 | $36.47 |
| Revenue Next Year | N/A | $39.31 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.18 | $3.42 |
| 52 Week High | $41.72 | $7.95 |
| Indicator | BNR | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 35.63 | 49.11 |
| Support Level | $15.52 | $3.79 |
| Resistance Level | $23.42 | $5.33 |
| Average True Range (ATR) | 1.39 | 0.24 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 11.27 | 81.82 |
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.